• Mission

    Spring Bank is devoted to pioneering its revolutionary SMNH chemistry platform to discover and develop a new generation of medicines to improve the lives of patients worldwide.
  • Our Technology

    Our proprietary small molecule nucleic acid hybrids (SMNH) chemistry platform produces a class of compounds designed to selectively target and modulate the activity of specific proteins implicated in various disease states with the favorable drug-like qualities of traditional small molecules.
  • Clinical Trials

    Get the latest information about our ongoing clinical trials.
  • Latest News

      • MAY 22, 2017

      Spring Bank Pharmaceuticals to Host Conference Call to Discuss Top-Line Results from the Initial Cohort of the Phase 2a Segment of its ACHIEVE Trial

      HOPKINTON, Mass., May 22, 2017 (GLOBE NEWSWIRE) — Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases, announced today that the company’s management team plans to host a conference call on Wednesday, May 24, 2017, at 8:00 a.m. ET, to discuss top-line results from the initial 25mg monotherapy dosing cohort of the Phase 2a segment of its ACHIEVE trial, a global, placebo-controlled, sequential-cohort, double-blind Phase 2 clinical trial for chronic Hepatitis B virus (HBV).

      The conference call may be accessed by dialing (866) 294-9216 for U.S. caller…

      Read more